Business
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, March 20, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2
About this update from Context Therapeutics Inc.
[{"type":"image","alt":"Context Therapeutics Inc.","displaySize":"","headline":null,"caption":"Context Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":140,"url":"https://media.zenfs.com/en/globenewswire.com/797f25b4cafd0f22a2578ccaa02e4a85"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YbSmZ9VBJ1k54h3C06aWkw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/797f25b4cafd0f22a2578ccaa02e4a85","width":300,"height":140}},"lazy":false},{"type":"text","content":"CTIM-76 first patient dosed in January 2025","length":43,"tagName":"p"},{"type":"text","content":"Cash and cash equivalents of $94.4 million as of December 31, 2024","length":66,"tagName":"p"},{"type":"text","content":"Company expects its cash and cash equivalents will continue to fund operations into 2027","length":88,"tagName":"p"},{"type":"text","content":"PHILADELPHIA, March 20, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2024, and reported on recent and upcoming business highlights.","length":361,"tagName":"p"},{"type":"text","content":"Martin Lehr, CEO of Context, commented, “We believe 2024 was a transformative year for Context, marked by strategic acquisitions, a strengthened financial position, and enhancements to our leadership team, all aligning with our mission to develop innovative T cell-engaging bispecific antibodies for solid tumors. With the expansion of our pipeline through the acquisition of CT-95 and the in-licensing of CT-202, as well as significant progress in our candidate, CTIM-76, we have positioned ourselves to make meaningful advancements in the treatment of solid tumors. As we entered 2025, we achieved a major milestone with the first patient dosed in our Phase 1 clinical trial of CTIM-76, a critical step in assessing its potential as a novel T cell-engaging bispecific antibody for CLDN6-positive ovarian, endometrial, and testicular cancers.”","length":844,"tagName":"p"},{"type":"text","content":"“We ended the year with cash and cash equivalents of $94.4 million, providing the financial resources needed to further advance our clinical programs...